News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
FDA Halts Review of Drugs From Ranbaxy Laboratories Plant
February 25, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Forbes -- U.S. regulators say India's largest drugmaker has falsified test results for some of its generic drugs.
Twitter
LinkedIn
Facebook
Email
Print
Asia
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Collaboration
Alphabet Subsidiary Calico Colors In Up To $570M+ Aging Deal With China’s Mabwell
June 27, 2025
·
2 min read
·
Tristan Manalac
Government
FDA Freezes Trials Shipping Cells to China, ‘Other Hostile Countries’
June 20, 2025
·
2 min read
·
Tristan Manalac
Antibody-drug conjugate (ADC)
NextCure Joins China-ADC Gold Rush with $745M Simcere Deal
June 16, 2025
·
1 min read
·
Dan Samorodnitsky
Autoimmune disease
Cullinan Bets $700M+ in Back-Heavy China Deal for Autoimmune T Cell Engager
June 5, 2025
·
2 min read
·
Tristan Manalac
